Michael S Kinch, Aayan Alwani, Tyler Schwartz, Zachary Kraft
An analysis of experimental medicines entering clinical trials from 2000 to 2024 reveals divergent patterns of development activity between the USA and China. Whereas China's ascent was consistent in the most common therapeutic category: small molecules, its rise was most pronounced in biologics-oriented categories, particularly cell therapy and monoclonal antibodies. By contrast, the USA retained comparatively greater shares in emerging modalities such as nucleic acid therapeutics and gene therapy. These findings add resolution to the phenomenon of Chinese near-parity with the USA in overall pharmaceutical output. The convergence is not uniform across modalities but instead reflects differential growth by drug type. Causal attribution of these patterns to specific policy or investment decisions warrants further investigation.